{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:13:20Z","timestamp":1780625600625,"version":"3.54.1"},"reference-count":68,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2015,1,2]]},"DOI":"10.1517\/14728214.2015.990373","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T08:38:27Z","timestamp":1417682307000},"page":"91-101","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":46,"title":["Emerging drugs for the treatment of acne"],"prefix":"10.1517","volume":"20","author":[{"given":"Imran","family":"Aslam","sequence":"first","affiliation":[{"name":"Wake Forest School of Medicine, Center for Dermatology Research, Department of Dermatology, Medical Center Boulevard","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Fleischer","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Center for Dermatology Research, Department of Dermatology, Medical Center Boulevard","place":["USA"]},{"name":"Wake Forest School of Medicine, Department of Pathology","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Feldman","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Center for Dermatology Research, Department of Dermatology, Medical Center Boulevard","place":["USA"]},{"name":"Wake Forest School of Medicine, Department of Pathology","place":["USA"]},{"name":"Wake Forest School of Medicine, Department of Public Health Sciences","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,12,4]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NPR.0000434089.88606.70"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.048"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.923401"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.852297"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.618"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.3.2.119"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200112150-00006"},{"issue":"6","key":"e_1_3_2_10_1","first-page":"658","article-title":"Tolerability of topical antimicrobials in treatment of acne vulgaris","volume":"13","author":"Bartlett KB","year":"2014","unstructured":"Bartlett KB, Davis SA, Feldman SR. Tolerability of topical antimicrobials in treatment of acne vulgaris. J Drugs Dermatol 2014;13(6):658-62","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.08.033"},{"key":"e_1_3_2_12_1","volume-title":"Draft guidance\/guidance for industry. Drug interaction studies \u2013 study design, data analysis, implications for dosing, and labeling recommendations","year":"2012","unstructured":"Draft guidance\/guidance for industry. Drug interaction studies \u2013 study design, data analysis, implications for dosing, and labeling recommendations. 2012"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.019"},{"key":"e_1_3_2_14_1","first-page":"13265","article-title":"Clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a Phase III, multicentre, randomised, single-blinded, active-controlled, parallel-group study","volume":"12","author":"Kawashima M","year":"2014","unstructured":"Kawashima M, Hashimoto H, Alio Saenz AB, et al. Clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a Phase III, multicentre, randomised, single-blinded, active-controlled, parallel-group study. Br J Dermatol 2014;12:13265","journal-title":"Br J Dermatol"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.21132"},{"key":"e_1_3_2_16_1","unstructured":"Petrou I. Experimental laser targets sebaceous glands to treat acne. 2012"},{"key":"e_1_3_2_17_1","unstructured":"Acne: who gets and causes. 2014"},{"issue":"6","key":"e_1_3_2_18_1","first-page":"611","article-title":"Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides","volume":"12","author":"Eichenfield LF","year":"2013","unstructured":"Eichenfield LF, Draelos Z, Lucky AW, et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides. J Drugs Dermatol 2013;12(6):611-18","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_19_1","unstructured":"Pharmaprojects. Epiduo. In. Citeline ed; 2014"},{"issue":"1","key":"e_1_3_2_20_1","first-page":"16","article-title":"The phototoxic and photoallergy potential of clindamycin phosphate 1.2%\/tretinoin 0.025% gel for facial acne: results of two single-center, evaluator-blinded, randomized, vehicle-controlled Phase 1 studies in healthy volunteers","volume":"13","author":"Murray J","year":"2014","unstructured":"Murray J, Potts A. The phototoxic and photoallergy potential of clindamycin phosphate 1.2%\/tretinoin 0.025% gel for facial acne: results of two single-center, evaluator-blinded, randomized, vehicle-controlled Phase 1 studies in healthy volunteers. J Drugs Dermatol 2014;13(1):16-22","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"e_1_3_2_21_1","first-page":"358","article-title":"Safety of a novel gel formulation of clindamycin phosphate 1.2%-tretinoin 0.025%: results from a 52-week open-label study","volume":"82","author":"Kircik LH","year":"2008","unstructured":"Kircik LH, Peredo MI, Bucko AD, et al. Safety of a novel gel formulation of clindamycin phosphate 1.2%-tretinoin 0.025%: results from a 52-week open-label study. Cutis 2008;82(5):358-66","journal-title":"Cutis"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1998.tb00974.x"},{"issue":"6","key":"e_1_3_2_23_1","first-page":"607","article-title":"Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris","volume":"6","author":"Schlessinger J","year":"2007","unstructured":"Schlessinger J, Menter A, Gold M, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol 2007;6(6):607-15","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2008.00862.x"},{"issue":"6","key":"e_1_3_2_25_1","first-page":"31","article-title":"Clindamycin 1.2% tretinoin 0.025% gel versus clindamycin gel treatment in acne patients: a focus on fitzpatrick skin types","volume":"4","author":"Schmidt N","year":"2011","unstructured":"Schmidt N, Gans EH. Clindamycin 1.2% tretinoin 0.025% gel versus clindamycin gel treatment in acne patients: a focus on fitzpatrick skin types. J Clin Aesthet Dermatol 2011;4(6):31-40","journal-title":"J Clin Aesthet Dermatol"},{"issue":"7","key":"e_1_3_2_26_1","first-page":"25","article-title":"Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color","volume":"5","author":"Callender VD","year":"2012","unstructured":"Callender VD, Young CM, Kindred C, et al. Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color. J Clin Aesthet Dermatol 2012;5(7):25-32","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"e_1_3_2_27_1","first-page":"318","article-title":"Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study","volume":"11","author":"Jarratt MT","year":"2012","unstructured":"Jarratt MT, Brundage T. Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study. J Drugs Dermatol 2012;11(3):318-26","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.16.2931"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.10.005"},{"issue":"10","key":"e_1_3_2_30_1","first-page":"981","article-title":"Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment","volume":"6","author":"Lucky AW","year":"2007","unstructured":"Lucky AW, Maloney JM, Roberts J, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol 2007;6(10):981-7","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"e_1_3_2_31_1","first-page":"15","article-title":"Cohort study on the treatment with dapsone 5% gel of mild to moderate inflammatory acne of the face in women","volume":"12","author":"Lynde CW","year":"2014","unstructured":"Lynde CW, Andriessen A. Cohort study on the treatment with dapsone 5% gel of mild to moderate inflammatory acne of the face in women. Skinmed 2014;12(1):15-21","journal-title":"Skinmed"},{"issue":"2","key":"e_1_3_2_32_1","first-page":"171","article-title":"Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents","volume":"81","author":"Raimer S","year":"2008","unstructured":"Raimer S, Maloney JM, Bourcier M, et al. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Cutis 2008;81(2):171-8","journal-title":"Cutis"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.186"},{"key":"e_1_3_2_34_1","unstructured":"Pharmaprojects. Minocycline foam. 2014"},{"issue":"4","key":"e_1_3_2_35_1","first-page":"21","article-title":"Safety and efficacy of a new extended-release formulation of minocycline","volume":"78","author":"Fleischer AB","year":"2006","unstructured":"Fleischer ABJr, Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline. Cutis 2006;78(4 Suppl):21-31","journal-title":"Cutis"},{"issue":"4","key":"e_1_3_2_36_1","first-page":"6","article-title":"Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets","volume":"78","author":"Plott RT","year":"2006","unstructured":"Plott RT, Wortzman MS. Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. Cutis 2006;78(4 Suppl):6-10","journal-title":"Cutis"},{"issue":"1248","key":"e_1_3_2_37_1","first-page":"95","article-title":"Extended-release minocycline (Solodyn) for acne","volume":"48","year":"2006","unstructured":"Extended-release minocycline (Solodyn) for acne. Med Lett Drugs Ther 2006;48(1248):95-6","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.4.459"},{"issue":"2","key":"e_1_3_2_39_1","first-page":"21","article-title":"The development of antibiotic resistance in Propionibacterium acnes","volume":"67","author":"Leyden J","year":"2001","unstructured":"Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis 2001;67(2 Suppl):21-4","journal-title":"Cutis"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2003.03014.x"},{"issue":"12","key":"e_1_3_2_41_1","first-page":"1149","article-title":"Subantimicrobial-dose doxycycline in the treatment of moderate facial acne","volume":"7","author":"Toossi P","year":"2008","unstructured":"Toossi P, Farshchian M, Malekzad F, et al. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol 2008;7(12):1149-52","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_42_1","unstructured":"Therapeutics N. Novan Announces Promising Results of SB204 Clinical Study. 2012"},{"key":"e_1_3_2_43_1","unstructured":"Kelce W. Topical nitric oxide as a first in class local antiandrgoen therapy for the treatment of acne and male pattern baldness."},{"key":"e_1_3_2_44_1","unstructured":"Novan\u2019s SB204 Could Be First Topical Sebum Inhibitor. 2013"},{"key":"e_1_3_2_45_1","unstructured":"Pharmaprojects. SB204 topical nitric oxide releasing sebum inhibitor. 2014"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2013.06.007"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2006.09.014"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S35334"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06110.x"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00046.x"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.12.033"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.9.1093"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2012.01427.x"},{"key":"e_1_3_2_54_1","unstructured":"Pharmaprojects. Cortodoxone. 2014"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10332.x"},{"key":"e_1_3_2_56_1","unstructured":"Pharmaprojects. Absorica. 2014"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.5289"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.045"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1473-2165.2010.00490.x"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fsc.2011.04.004"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.2165\/11631410-000000000-00000"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.060"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2014.26.1.43"},{"issue":"8","key":"e_1_3_2_64_1","first-page":"919","article-title":"Digital videography assessment of patients\u2019 experiences using adapalene-benzoyl peroxide gel in the treatment of acne vulgaris","volume":"11","author":"Feldman SR","year":"2012","unstructured":"Feldman SR, Fried RG, Herndon JHJr, et al. Digital videography assessment of patients\u2019 experiences using adapalene-benzoyl peroxide gel in the treatment of acne vulgaris. J Drugs Dermatol 2012;11(8):919-25","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.643221"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12013"},{"issue":"5","key":"e_1_3_2_67_1","first-page":"16","article-title":"The tolerability profile of clindamycin 1%\/benzoyl peroxide 5% gel vs. adapalene 0.1%\/benzoyl peroxide 2.5% gel for facial acne: results of two randomized, single-blind, split-face studies","volume":"5","author":"Green L","year":"2012","unstructured":"Green L, Cirigliano M, Gwazdauskas JA, et al. The tolerability profile of clindamycin 1%\/benzoyl peroxide 5% gel vs. adapalene 0.1%\/benzoyl peroxide 2.5% gel for facial acne: results of two randomized, single-blind, split-face studies. J Clin Aesthet Dermatol 2012;5(5):16-24","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"e_1_3_2_68_1","first-page":"91","article-title":"Randomized, observer-blind, split-face study to compare the irritation potential of 2 topical acne formulations over a 14-day treatment period","volume":"90","author":"Ting W","year":"2012","unstructured":"Ting W. Randomized, observer-blind, split-face study to compare the irritation potential of 2 topical acne formulations over a 14-day treatment period. Cutis 2012;90(2):91-6","journal-title":"Cutis"},{"issue":"12","key":"e_1_3_2_69_1","first-page":"1422","article-title":"A double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin\/tretinoin and benzoyl peroxide\/adapalene","volume":"11","author":"Goreshi R","year":"2012","unstructured":"Goreshi R, Samrao A, Ehst BD. A double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin\/tretinoin and benzoyl peroxide\/adapalene. J Drugs Dermatol 2012;11(12):1422-6","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_70_1","unstructured":"Orrange S. Absorica: new pill for acne hits the market. 2012"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14728214.2015.990373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:48:12Z","timestamp":1770940092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14728214.2015.990373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,4]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,2]]}},"alternative-id":["10.1517\/14728214.2015.990373"],"URL":"https:\/\/doi.org\/10.1517\/14728214.2015.990373","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}